Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2024 | $16.00 → $9.00 | Buy → Neutral | Mizuho |
| 1/9/2024 | $30.00 → $8.00 | Buy → Neutral | Goldman |
| 8/16/2023 | $20.00 | Underperform → Neutral | Exane BNP Paribas |
| 10/11/2022 | $27.00 | Equal-Weight | Morgan Stanley |
| 9/22/2022 | $33.00 | Buy | Goldman |
| 10/26/2021 | $33.00 → $22.00 | Overweight | Barclays |
| 10/25/2021 | $17.00 | Overweight → Equal-Weight | Wells Fargo |
| 10/18/2021 | $45.00 → $25.00 | Buy | Needham |
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
10-Q - Revance Therapeutics, Inc. (0001479290) (Filer)
8-K - Revance Therapeutics, Inc. (0001479290) (Filer)
Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company Brings together two high-quality, complementary product lines Combined company's flagship brands to include DAXXIFY® (toxin), the RHA® Collection (filler), SkinPen® (microneedling), PanOxyl® (acne), Blue Lizard® (sunscreen), and StriVectin® (anti-aging) Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel New product flow potential through internal product development and an integrated manufacturing operation Experienced leadership team that leverages the st
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at
Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois. Goldman Sachs 45th Annual Global Healthcare Conference President and Chief Executive Officer Mark J. Foley is scheduled to present on Tuesday, June 11, 2024, at 8:00 am ET, in Miami, Florida. Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be availab
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
Conference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August 8, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 or other locations and reference conference ID 218406, or from the webcast link in the investor relations section of the company's website at
Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 663066, or from the webcast link in the investor relations section of the company's website at www.
Conference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update. Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S callers and (929) 526-1599 for other locations and reference conference ID 643827, or from the webcast link in the investor relations section of the com
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G/A - Revance Therapeutics, Inc. (0001479290) (Subject)
SC 13G - Revance Therapeutics, Inc. (0001479290) (Subject)
4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
Mizuho downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $9.00 from $16.00 previously
Goldman downgraded Revance Therapeutics from Buy to Neutral and set a new price target of $8.00 from $30.00 previously
Exane BNP Paribas upgraded Revance Therapeutics from Underperform to Neutral and set a new price target of $20.00
HC Wainwright & Co. analyst Douglas Tsao maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and lowers the price target from $12 to $11.
Goldman Sachs analyst Chris Shibutani maintains Revance Therapeutics (NASDAQ:RVNC) with a Neutral and lowers the price target from $9 to $8.
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results. Diodes posted adjusted earnings of 28 cents per share, missing market estimates of 31 cents per share. The company's quarterly sales came in at $301.97 million missing expectations of $305.01 million, according to data from Benzinga Pro. Diodes shares dipped 9.8% to $68.99 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novavax, Inc. (NASDAQ:NVAX) shares jumped 139% to $10.73 after the company and Sanofi announced a co-exclusive licensing agreement to commercialize a COVID-19 vaccine and d
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:
Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:
EDMONTON, AB, Nov. 17, 2022 /PRNewswire/ - Nanostics Inc., a precision health diagnostics company, announced today the appointment of Aubrey Rankin to its Board of Directors. Mr. Rankin will join the board of directors at Nanostics replacing Mr. Reg Joseph as one of the independent directors for the company. "We're excited to announce Aubrey Rankin's appointment to Nanostics' Board of Directors. Aubrey's vast experience and insights with patient-provider subscription platforms will be invaluable as we launch our lead prostate cancer diagnostic test, ClarityDX Prostate®," said
- Q1 revenue for the RHA® Collection of dermal fillers of $11.6 million - HintMD's processing volume run-rate more than doubled to over $400 million from the prior quarter - Over 1,500 aesthetic accounts activated across products and services at quarter-end - Status of the U.S. Food and Drug Administration (FDA) pre-approval inspection - Conference call and webcast today at 4:30 p.m. ET Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. Financial Highlights Revenue for the first quarter 2021 totaled $
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra